Heart Research September 2007: 0-0
Efficacy of non-invasive ventilation in patients with acute cardiogenic pulmonary oedema: The 3CPO trial.
Austria, Vienna, 2 September 2007: Acute cardiogenic pulmonary oedema, or "fluid on the lung", is a common, extremely distressing and often fatal condition that is a major consumer of health care resources. The aim of the 3CPO trial was to establish whether high-pressure oxygen, given by a simple facemask, could help reduce the death rate in patients with this condition. The 3CPO trial, led by Dr Alasdair Gray, was undertaken over three years in 26 Emergency Departments across the UK and recruited over 1,000 patients with this severe life-threatening condition. The study established that administering oxygen at high pressure (so-called non-invasive ventilation) did speed up the recovery of these patients irrespective of how this was performed. However, non-invasive ventilation did not influence whether the patient ultimately died. This first major large scale clinical trial has demonstrated that non-invasive ventilation is a useful treatment to alleviate distress and improve breathing in patients with "fluid on the lung" but that it does not improve their subsequent chances of survival.The Disease:
This trial addressed the very serious and potentially fatal
condition of acute cardiogenic pulmonary oedema or "fluid on the
lung". In this condition, the heart suddenly fails to pump blood
effectively around the body. This causes a build up of blood behind
the heart leading to an increase in pressure that floods the lungs
with fluid. The patient experiences extreme breathlessness and
distress, and may rapidly deteriorate such that they need to go
onto a ventilator. This is a devastating condition that kills 1 in
6 sufferers, and accounts for 15-20,000 hospital admissions per
year in the UK and 6.5 million hospital days in the US. Thus, this
is a serious, potentially fatal condition that has a major impact
on health care provision.
The Treatment:
The main treatment of this condition focuses on using oxygen and
drugs to clear the lung of fluid and help the heart recover.
Numerous small studies of 20-50 patients have suggested that
increasing the pressure of oxygen may help improve the outcome of
this condition. Rather than inserting a tube into the lung, this
can be achieved by applying a tightly fitting facemask with oxygen
blown in at pressure, so-called non-invasive ventilation. This can
be performed by using a constant pressure (continuous positive
pressure ventilation or CPAP) or at low pressure when breathing out
and high pressure when breathing in (non-invasive intermittent
positive pressure ventilation, NIPPV).
The purpose of the 3CPO trial was to determine whether non-invasive
ventilation can improve the death rate of this condition, and which
method (CPAP or NIPPV) should be used, as this has not been
established . Since the study started, several papers have
suggested that the total evidence to date indicates non-invasive
ventilation should halve the rate of death in this condition.
The Trial:
The trial was funded by the National Health Service Health
Technology Assessment Programme of the Department of Health,
England. It was conducted over the last 3 years and was based in
the Emergency Departments of 26 centres throughout the United
Kingdom. Patients went into the trial immediately on arrival at the
hospital and were only eligible if they were very breathless and
had evidence that the body was struggling to cope (the blood had
become acidic).
The Results:
At the close of the trial, 1,069 patients were recruited and
received either standard oxygen (367 patients), CPAP (346 patients)
or NIPPV (356 patients). In comparison to standard oxygen
treatment, both forms of non-invasive ventilation produced better
rates of recovery with a more rapid fall in the breathing and heart
rate as well as a quicker resolution of the acidity in the blood.
However, the death rate did not differ (see Figure). There were no
differences in responses according to which type of treatment (CPAP
or NIPPV) was used.
The Implications:
This is the first large scale clinical trial to test whether giving
oxygen at high pressure can help patients with this serious life
threatening condition. It has shown that, irrespective of the
method of administration, non-invasive ventilation helps patients
to recover more quickly in the first few hours of their illness but
that this does not improve their subsequent chances of
survival.
Notes to editors:
This study was presented at the ESC Congress 2007 in Vienna,
Austria.
The European Society of Cardiology (ESC):
The ESC represents nearly 53,000 cardiology professionals across
Europe and the Mediterranean. Its mission is to reduce the burden
of cardiovascular disease in Europe.
The ESC achieves this through a variety of scientific and educational activities including the coordination of: clinical practice guidelines, education courses and initiatives, pan-European surveys on specific disease areas and the ESC Annual Congress, the largest medical meeting in Europe. The ESC also works closely with the European Commission and WHO to improve health policy in the EU.
The ESC comprises 3 Councils, 5 Associations, 19 Working Groups, 50 National Cardiac Societies and an ESC Fellowship Community (Fellow, FESC; Nurse Fellow, NFESC). For more information on ESC Initiatives, Congresses and Constituent Bodies see www.escardio.org.
European Society of Cardiology, The European Heart House 2035 Route des Colles, B.P. 179 - Les Templiers, Sophia Antipolis F-06903 France
About the Author
Professor David Newby
Royal Infirmary, Edinburgh, UK
Comments
Be the first to comment on this!
You must sign in to comment Sign In or Create an Account to add comments